2017 PUBLICATIONS MEDIA KIT





Founded in 1907, the American Association for Cancer Research (AACR) is the first and largest scientific organization in the world focused on every aspect of high-quality, innovative cancer research. For over a century, our mission has always been to prevent and cure cancer through research, education, communication, and collaboration.

The AACR currently publishes a portfolio of eight peer-reviewed journals that cover the full spectrum of cancer research. Our exceptional scientific editors, outstanding editorial boards, and committed publishing professionals all work diligently to establish the highest scholarly standards and provide the highest quality of content. Our reputation for scientific breadth and excellence continues to attract the premier researchers in the field. We are proud to note that 4 of our journals rank in the top 20 of oncology journals with regards to Impact Factor, and while AACR publishes 3.8% of the articles in the oncology category, these articles garner almost 17% of citations across cancer research, according to 2015 *Journal Citation Reports*® (Thomson Reuters 2016). Additionally, in 2016, the AACR journals had over 60 million views, which translates to 1 view every 0.53 seconds.



For More Information:

Daniel Simone National Accounts Manager Pharmaceutical Media Inc. dsimone@pminy.com 212-904-0360

Michael Perlowitz National Accounts Manager Pharmaceutical Media, Inc. mperlowitz@pminy.com 212-904-0374

Monica Griffiths
Print Production Coordinator
Pharmaceutical Media, Inc.
mgriffiths@pminy.com
212-904-0362



Cancer Research

Driving innovation to prevent and cure cancer

As one of the most frequently cited and well-respected cancer journals in the world, *Cancer Research* publishes original studies, reviews, and opinion pieces offering significance and broad impact to a diverse audience spanning basic, preclinical, clinical, prevention, and epidemiologic research. *Cancer Research* seeks manuscripts that offer pathobiological and translational impact to inform the personal, clinical, and societal problems posed by cancer. The main scope of the Journal is captured in its primary subsections, which focus on molecular and cellular pathobiology, tumor and stem cell biology, therapeutics and targets, microenvironment and immunology, prevention and epidemiology, and integrated systems and technology.

Impact Factor: 8.556 (2015)

Frequency: Semi-monthly print issues

Print Circulation: 1,200

First Published: 1941

Peer Reviewed: Yes

Editor-in-Chief: George C. Prendergast, PhD,

Lankenau Institute for Medical Research (Wynnewood, PA)

	Commitment and
Issue Date	Material Deadline
1/1/2017	12/1
1/15/2017	12/15
2/1/2017	1/4
2/15/2017	1/13
3/1/2017	1/30
3/15/2017	2/13
4/1/2017*	3/1
4/15/2017	3/15
5/1/2017	4/3
5/15/2017	4/17
6/1/2017	5/1
6/15/2017	5/15
7/1/2017	6/1
7/15/2017	6/15
8/1/2017	7/3
8/15/2017	7/17
9/1/2017	7/31
9/15/2017	8/15
10/1/2017	9/1
10/15/2017	9/15
11/1/2017	10/2
11/15/2017	10/16
12/1/2017	11/1
12/15/2017	11/15
*Annual Meeting I	ssue

Cancer Research Rates

Print Advertising

Frequency	1x	Multiple
Full Page	\$1,885	\$1,710
1/2 Page	\$1,200	\$1,100
1/4 Page	\$875	\$775

4-Color Rates: \$700 (in addition to B/W rates)

Typesetting Fee:

Full Page: \$200 ½ Page: \$150 ¼ Page: \$125

Digital Advertising

Website Statistics

171,350 users/month 740,420 page views/month 363,000 sessions/month

Banner Ads

728,000 impressions/month Global \$45.00 CPM USA Only \$50.00 CPM

ETOCs

26,215 recipients/2X per month Buy 1 eTOC \$1800 net Buy 2 eTOCs \$3000 net Buy 3 eTOCs \$4500 net Buy ALL eTOCs \$8000 net



Clinical Cancer Research

Clinical and translational research bridging the laboratory and the clinic

Clinical Cancer Research focuses on innovative clinical and translational cancer research studies that bridge the laboratory and the clinic. The Journal is especially interested in clinical trials evaluating new treatments, accompanied by research on pharmacology and molecular alterations or biomarkers that predict response or resistance to treatment. The Journal also prioritizes laboratory and animal studies of new drugs and molecule-targeted agents with the potential to lead to clinical trials and studies of targetable mechanisms of oncogenesis, progression of the malignant phenotype, and metastatic disease.

Impact Factor: 8.738 (2015)

Frequency: Semi-monthly print issues

Print Circulation: 820
First Published: 1995
Peer Reviewed: Yes

Editor-in-Chief: Kenneth C. Anderson, MD, Dana-Farber

Cancer Institute (Boston, MA)

Issue Date	Commitment and Material Deadline
1/1/2017	12/1
1/15/2017	12/15
2/1/2017	1/4
2/15/2017	1/13
3/1/2017	1/30
3/15/2017	2/13
4/1/2017*	3/1
4/15/2017	3/15
5/1/2017	4/3
5/15/2017	4/17
6/1/2017	5/1
6/15/2017	5/15
7/1/2017	6/1
7/15/2017	6/15
8/1/2017	7/3
8/15/2017	7/17
9/1/2017	7/31
9/15/2017	8/15
10/1/2017	9/1
10/15/2017	9/15
11/1/2017	10/2
11/15/2017	10/16
12/1/2017	11/1
12/15/2017	11/15
*Annual Meeting	•

Clinical Cancer Research Rates

Print Advertising

Frequency	1x	Multiple
Full Page	\$1,125	\$1,025
1/2 Page	\$750	\$650
1/4 Page	\$525	\$425

4-Color Rates: \$700 (in addition to B/W rates)

Typesetting Fee:

Full Page: \$200 ½ Page: \$150 ¼ Page: \$125

Digital Advertising

Website Statistics

110,000 users/month 438,200 page views/month 214,000 sessions/month

Banner Ads

440,000 impressions/month Global \$45.00 CPM USA Only \$50.00 CPM

ETOCs

20,094 recipients/2X per month Buy 1 eTOC \$1800 net Buy 2 eTOCs \$3000 net Buy 3 eTOCs \$4500 net Buy ALL eTOCs \$8000 net



CANCER DISCOVERY

The essential information source to serve the diverse professional community in cancer science and medicine

Cancer Discovery publishes paradigm-changing, peer-reviewed articles describing major advances in research and clinical trials. Cancer Discovery also publishes review articles, perspectives and commentaries, news, and Research Watch summaries of important journal articles. Topics span the spectrum of cancer research and medicine, from the laboratory to the clinic to epidemiologic studies.

Impact Factor: 19.783 (2015)

Frequency: Monthly print issues

Print Circulation: 1,100

First Published: 2011

Peer Reviewed: Yes

Editors-in-Chief: Lewis C. Cantley, PhD, Weill Cornell Medical College and NewYork-Presbyterian Hospital

(New York, NY)

José Baselga, MD, PhD, Memorial Sloan Kettering

Cancer Center (New York, NY)

Issue Date	Commitment and Material Deadline
1/1/2017	12/2
2/1/2017	1/6
3/1/2017	2/3
4/1/2017*	3/3
5/1/2017	4/3
6/1/2017	5/5
7/1/2017	6/2
8/1/2017	7/7
9/1/2017	8/4
10/1/2017	9/5
11/1/2017	10/6
12/1/2017	11/3

^{*}Annual Meeting Issue

Cancer Discovery Rates

Print Advertising

Frequency	1x	Multiple
Full Page	\$1,125	\$1,025
1/2 Page	\$750	\$650
1/4 Page	\$525	\$425

4-Color Rates: \$700 (in addition to B/W rates)

Typesetting Fee:

Full Page: \$200 ½ Page: \$150 ¼ Page: \$125

Digital Advertising

Website Statistics

30,000 users/month 140,180 page views/month 58,200 sessions/month

Banner Ads

145,000 impressions/month Global \$45.00 CPM USA Only \$50.00 CPM

ETOCs

16,267 recipients per month Buy 1 eTOC \$1800 net Buy 2 eTOCs \$3000 net Buy 3 eTOCs \$4500 net Buy ALL eTOCs \$8000 net



Molecular Cancer Therapeutics

The journal of cancer drug discovery and preclinical development

Molecular Cancer Therapeutics focuses on basic research that has implications for cancer therapeutics in the following areas: experimental cancer therapeutics, identification of molecular targets, targets for chemoprevention, new models, cancer chemistry and drug discovery, molecular and cellular pharmacology, molecular classification of tumors, and bioinformatics and computational molecular biology.

Impact Factor: 5.579 (2015)

Frequency: Monthly print issues

Print Circulation: 210 **First Published:** 2001

Peer Reviewed: Yes

Editor-in-Chief: Napoleone Ferrara, MD, UC San Diego

Moores Cancer Center (La Jolla, CA)

Commitment and Material Deadline
12/2
1/3
2/6
3/3
3/31
5/1
6/1
7/3
8/4
9/5
10/2
11/1

^{*}Annual Meeting Issue

Molecular Cancer Therapeutics Rates

Print Advertising

Frequency	1x	Multiple
Full Page	\$855	\$755
1/2 Page	\$585	\$485
1/4 Page	\$450	\$350

4-Color Rates: \$700 (in addition to B/W rates)

Typesetting Fee:

Full Page: \$200 ½ Page: \$150 ¼ Page: \$125

Digital Advertising

Website Statistics

44,000 users/month 145,500 page views/month 76,000 sessions/month

Banner Ads

143,000 impressions/month Global \$45.00 CPM USA Only \$50.00 CPM **ETOCs**

13,934 recipients per month Buy 1 eTOC \$1800 net Buy 2 eTOCs \$3000 net Buy 3 eTOCs \$4500 net Buy ALL eTOCs \$8000 net



Cancer Epidemiology, Biomarkers & Prevention

Translating cancer science to populations

Cancer Epidemiology, Biomarkers & Prevention publishes original peer-reviewed, population-based research on cancer etiology, prevention, surveillance, and survivorship. The following topics are of special interest: descriptive, analytical, and molecular epidemiology; biomarkers, including assay development, validation, and application; chemoprevention and other types of prevention research in the context of descriptive and observational studies; the role of behavioral factors in cancer etiology and prevention; survivorship studies; and risk factors and the science of cancer health disparities. Besides welcoming manuscripts that address individual subjects in any of the relevant disciplines, the Editors of Cancer Epidemiology, Biomarkers & Prevention encourage the submission of manuscripts with a transdisciplinary approach.

Impact Factor: 3.622 (2015)

Frequency: Monthly print issues

Print Circulation: 250 First Published: 1991

Peer Reviewed: Yes

Editor-in-Chief: Timothy R. Rebbeck, PhD, Dana-Farber

Cancer Institute and Harvard T.H. Chan School of Public Health

(Boston, MA)

Issue Date	Commitment and Material Deadline
1/1/2017	12/7
2/1/2017	1/4
3/1/2017	2/2
4/1/2017*	3/3
5/1/2017	3/31
6/1/2017	4/28
7/1/2017	6/6
8/1/2017	7/3
9/1/2017	7/31
10/1/2017	9/5
11/1/2017	10/5
12/1/2017	11/3

^{*}Annual Meeting Issue

Cancer Epidemiology, Biomarkers & Prevention Rates

Print Advertising

Frequency	1x	Multiple
Full Page	\$855	\$755
1/2 Page	\$585	\$485
1/4 Page	\$450	\$350

4-Color Rates: \$700 (in addition to B/W rates)

Typesetting Fee:

Full Page: \$200 ½ Page: \$150 ¼ Page: \$125

Digital Advertising

Website Statistics

54,400 users/month 142,000 page views/month 77,000 sessions/month

Banner Ads

134,000 impressions/month Global \$45.00 CPM USA Only \$50.00 CPM

ETOCs

14,697 recipients per month Buy 1 eTOC \$1800 net Buy 2 eTOCs \$3000 net Buy 3 eTOCs \$4500 net Buy ALL eTOCs \$8000 net



Cancer Immunology Research

Illuminating the interplay of cancer and the immune system

Cancer Immunology Research publishes outstanding original articles reporting major advances in cancer immunology that span the discipline from basic investigations in host-tumor interactions to developmental therapeutics in model systems, early translational studies in patients, and late-stage clinical trials. The Journal disseminates knowledge of immunology to the cancer research community, catalyzing cross-disciplinary work that yields a deeper understanding of the host-tumor relationship, more potent cancer treatments, and improved clinical outcomes. Specific topics of interest include endogenous antitumor immunity, tumor-promoting inflammation, cancer antigens, vaccines, antibodies, cellular therapy, cytokines, immune regulation, immune suppression, immunomodulatory effects of cancer treatment, emerging technologies, and clinical investigations.

Impact Factor: 6.665 (2015)

Frequency: Monthly print issues

Print Circulation: 540

First Published: 2013

Peer Reviewed: Yes

Editors-in-Chief: Robert D. Schreiber, PhD, Washington University (St. Louis, MO) and Philip D. Greenberg, MD, PhD, Fred Hutchinson Cancer Research Center (Seattle, WA)

	Commitment and
Issue Date	Material Deadline
1/1/2017	12/2
2/1/2017	1/6
3/1/2017	2/1
4/1/2017*	3/1
5/1/2017	4/3
6/1/2017	5/4
7/1/2017	6/2
8/1/2017	7/6
9/1/2017	8/4
10/1/2017	9/5
11/1/2017	10/2
12/1/2017	11/1

^{*}Annual Meeting Issue

Cancer Immunology Research Rates

Print Advertising

Frequency	1x	Multiple
Full Page	\$1,060	\$960
1/2 Page	\$725	\$625
1/4 Page	\$505	\$405

4-Color Rates: \$700 (in addition to B/W rates)

Typesetting Fee: Full Page: \$200 ½ Page: \$150 ¼ Page: \$125

Digital Advertising

Website Statistics 15,000 users/month 56,000 page views/month 26,000 sessions/month

Banner Ads 55,000 impressions/month Global \$45.00 CPM USA Only \$50.00 CPM

ETOCs

346 recipients per month Buy 1 eTOC \$1800 net Buy 2 eTOCs \$3000 net Buy 3 eTOCs \$4500 net Buy ALL eTOCs \$8000 net



Cancer Prevention Research

The forefront of prevention science

Cancer Prevention Research publishes important original studies, reviews, and perspectives within the major topic areas of biology of premalignancy; risk factors and risk assessment; early detection research; immunoprevention; and chemopreventive and other interventions, including the basic science behind them. Cancer Prevention Research comprises preclinical, clinical, and translational research, with special attention given to molecular discoveries and an emphasis on building a translational bridge between the basic and clinical sciences.

Impact Factor: 3.887 (2015)

Frequency: Monthly print issues

Print Circulation: 150

First Published: 2008

Peer Reviewed: Yes

Editor-in-Chief: Scott M. Lippman, MD, UC San Diego

Moores Cancer Center (La Jolla, CA)

	Commitment and
Issue Date	Material Deadline
1/1/2017	12/2
2/1/2017	1/6
3/1/2017	2/1
4/1/2017*	3/1
5/1/2017	4/3
6/1/2017	5/4
7/1/2017	6/2
8/1/2017	7/6
9/1/2017	8/4
10/1/2017	9/5
11/1/2017	10/2
12/1/2017	11/1

^{*}Annual Meeting Issue

Cancer Prevention Research Rates

Print Advertising

Frequency	1x	Multiple
Full Page	\$855	\$755
1/2 Page	\$585	\$485
1/4 Page	\$450	\$350

4-Color Rates: \$700 (in addition to B/W rates)

Typesetting Fee: Full Page: \$200

½ Page: \$150 ¼ Page: \$125

Digital Advertising

Website Statistics

16,000 users/month 43,000 page views/month 22,300 sessions/month

Banner Ads

45,000 impressions/month Global \$45.00 CPM USA Only \$50.00 CPM **ETOCs**

12,181 recipients per month Buy 1 eTOC \$1800 net Buy 2 eTOCs \$3000 net Buy 3 eTOCs \$4500 net Buy ALL eTOCs \$8000 net



Molecular Cancer Research

Defining the molecular basis of malignancy and progression

Molecular Cancer Research publishes articles describing novel basic cancer research discoveries of broad interest to the field. Areas of emphasis include all cancer-associated pathways (including cell-cycle regulation; cell death; chromatin regulation; DNA damage and repair; gene and RNA regulation; genomics; oncogenes and tumor suppressors; and signal transduction), in addition to studies describing new molecular mechanisms and interactions that support cancer phenotypes.

Impact Factor: 4.51 (2015)

Frequency: Monthly print issues

Print Circulation: 160
First Published: 2002

Peer Reviewed: Yes

Editor-in-Chief: Karen E. Knudsen, PhD,

Sidney Kimmel Cancer Center, Thomas Jefferson University

(Philadelphia, PA)

Issue Date	Commitment and Material Deadline
1/1/2017	12/2
2/1/2017	1/6
3/1/2017	2/1
4/1/2017*	3/1
5/1/2017	4/3
6/1/2017	5/4
7/1/2017	6/2
8/1/2017	7/6
9/1/2017	8/4
10/1/2017	9/5
11/1/2017	10/2
12/1/2017	11/1

^{*}Annual Meeting Issue

Molecular Cancer Reserch Rates

Print Advertising

Frequency		1x	Multiple
Full Page	\$1	,060	\$960
1/2 Page	\$	725	\$625
1/4 Page	\$	505	\$405

4-Color Rates: \$700 (in addition to B/W rates)

Typesetting Fee: Full Page: \$200 ½ Page: \$150 ¼ Page: \$125

Digital Advertising

Website Statistics 21,400 users/month 62,200 page views/month 32,700 sessions/month

Banner Ads 66,370 impressions/month Global \$45.00 CPM USA Only \$50.00 CPM

ETOCs

13,297 recipients per month Buy 1 eTOC \$1800 net Buy 2 eTOCs \$3000 net Buy 3 eTOCs \$4500 net Buy ALL eTOCs \$8000 net



Banner Ads

- 2,100,000 impressions/month across the AACR Journal platform
- 337,000 impressions/month on Home and Other Pages

AACR Journal Websites	720 v 00 (leadeth actal)
Ad Unit Sizes:	728 x 90 (leaderboard)
	120/160/300 x 600
	300 x 250
Anchor ad	728/970 x 90, 300 x 50 (mobile)
Creative Types:	GIFs, JPEGs, and SWFs
Max. File Size:	99KB

AACR Journals Platform Redesign

To keep up with the growing needs of the cancer research community, the AACR has redesigned its journal websites with a focus on readability and enhanced features. Advertisements have greater visibility with the new addition of anchor banners.

3rd Party Tags Accepted (DFA, MediaMind, Pointroll, etc.)

Electronic Table of Contents (eTOC) Advertising

AACR Journal Emails (eTOCs)
Ad Unit Size - 500 x 100

Electronic Table of Contents Specs:

Creative Types: GIFs and JPEGs


• Creative Sizes: 500 x 100

• Max File Size: 39 KB

• 3rd Party Tags:

Yes, 1 x 1 Pixel For Impression Tracking


- Can creative be animated: No, static only
- Optional: Text ad served to users who receive plain text emails rather than HTML.
 (50 words max, includes content of the text ad and the click URL provided.




Please send all materials to: Samir Delgado adops@pminy.com // 212-904-0369 Please send all insertion orders to:
Daniel Simone
dsimone@pminy.com // 212-904-0360



DIGITAL ADVERTISING





Production and Mechanical Requirements

(all AACR publications)

Mechanical Specifications:		
Trim Size:	8.125 x 10.875	
Live Area:	Keep live matter .5" from trim	
Binding:	Perfect	
Paper Stock:	50 lb. matte (50 lb. glossy for <i>Cancer Discovery</i>)	
Halftone Screen:	133-150	

Mechanical Requirements:			
	on-Bleed Sizes width x height	Bleed Sizes width x height	
Full Page	7" x 10"	8.375" x 11.1875"	
Half Page Horizontal	7" x 5"	8.375" x 5.4375"	
Half Page Vertical	3.5" x 10"	4.0625" x 11.1875"	
Quarter Page	3.5" x 5"	n/a	

Reproduction Requirements:

- PDF format is the preferred file format for file submission.
- Only use Type 1 fonts No true type fonts.
- Images must be SWOP (CMYK or Grayscale) TIFF or EPS between 266 and 400 dpi.
- Total area density should not exceed SWOP 300% TAC.
- Do not embed ICC profiles within images. Do not use RGB or JPEG images.
- Do not nest EPS files within other EPS files.

Print Production Coordinator: Monica Griffiths: Pharmaceutical Media, Inc.

mgriffiths@pminy.com


212-904-0362



U.S.

Non-U.S.

*Based on 2016 subscriptions





For More Information:

Daniel Simone
National Accounts Manager
Pharmaceutical Media Inc.
dsimone@pminy.com
212-904-0360

Michael Perlowitz
National Accounts Manager
Pharmaceutical Media, Inc.
mperlowitz@pminy.com
212-904-0374

Monica Griffiths
Print Production Coordinator
Pharmaceutical Media, Inc.
mgriffiths@pminy.com
212-904-0362

